Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder
This case report provides Class IV evidence that eculizumab should be stopped with caution and switched to another treatment immediately. This is a single observational study without controls.
Authors
- Bruno Stankoff (ORCID: https://orcid.org/0000-0002-9631-4674)
- Anne‐Laure Dubessy (ORCID: https://orcid.org/0000-0002-8148-9279)
- Ysoline Beigneux (ORCID: https://orcid.org/0000-0001-5749-1865)
- Natalia Shor (ORCID: https://orcid.org/0000-0003-0693-1829)
- Élisabeth Maillart (ORCID: https://orcid.org/0000-0001-7699-0328)
- Catherine Lubetzki (ORCID: https://orcid.org/0000-0001-7164-3175)
- René Decombe
- Romain Marignier (ORCID: https://orcid.org/0000-0002-5967-2800)
- Mathilde Piljan
Institutions
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Pierre Wertheimer (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre Hospitalier de Troyes (FR)
Publication Details
- Journal
- Neurology
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1212/wnl.0000000000213399
- Citations
- 4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.89